▲MarkerX Team awarded the “Best Poster Award” at the Clinical Mass Spectrometry Conference in Asia 2026 (CMSCA). The award-winning presentation by Po-Hsin Kong, in collaboration with NTU Cancer Center, highlights MarkerX’s leadership in clinical proteomics and precision medicine, validating our R&D excellence on an international academic stage.
We are thrilled to announce that the MarkerX R&D team has been honored with the Best Poster Award at the 2026 Clinical Mass Spectrometry Conference Asia (CMSCA 2026), which concluded this past weekend.
Our award-winning research, titled “Optimization of an FFPE Tissue Proteomic Workflow,” stood out among numerous outstanding academic presentations. We extend our deepest gratitude to the organizing committee and the judges for recognizing our research capabilities. A special thank you goes to the NTU Cancer Center for their long-term clinical insights and collaborative spirit.
Overcoming Clinical Pain Points: A Breakthrough in Routine Tissue Analysis
The core innovation of this research lies in the successful optimization of a highly efficient proteomic workflow specifically designed for Formalin-Fixed Paraffin-Embedded (FFPE) tissues.
In the development of precision medicine, specimen preservation and transport are critical. While “fresh frozen tissue” is the gold standard for proteomics, it is often impractical in routine clinical settings. Most precious clinical samples are stored as FFPE. However, FFPE samples suffer from severe protein degradation and chemical cross-linking, leading to low recovery rates and poor identification quality—until now.
Three Core Breakthroughs: Enhanced Identification, MRD for Micro-samples, and Amyloidosis Diagnostics
Developed in collaboration with Dr. Chao-Hung Wei’s team at NTU Cancer Center, this research highlights three game-changing outcomes:
1. Significant Boost in Protein Recovery and Identification
By utilizing optimized thermal denaturation and surfactant technologies, we successfully identified 3,253 proteins in FFPE tissues. Crucially, our workflow demonstrated a high correlation with fresh frozen tissue (Pearson r = 0.81), with a protein overlap exceeding 92%. This proves that high-quality data, comparable to fresh samples, can be extracted from routine FFPE specimens.
2. Achieving MRD Analysis in Micro-samples
Using Laser-Capture Microdissection (LCM), our team challenged the limits by analyzing minute tissue sections of only 200,000 µm². Even with such tiny samples, we stably identified over 500 high-quality proteins. This is a milestone for diagnosing conditions where samples are extremely small and difficult to obtain, such as cardiac biopsies. Imagine the possibilities: your existing archival samples can now be re-powered by this technology to develop new diagnostic methods!
3. Clinical Validation in Amyloidosis Diagnostics
We have applied this workflow to actual cardiac biopsy samples to differentiate Transthyretin Amyloidosis (ATTR) from other subtypes. The results showed 100% consistency between mass spectrometry identification and traditional pathological diagnosis. This offers a powerful new methodology for rare diseases that are traditionally difficult to diagnose early.
Overcoming Clinical Pain Points: A Breakthrough in Specimen Logistics
The core innovation of this research lies in the successful optimization of a highly efficient proteomic workflow specifically designed for Formalin-Fixed Paraffin-Embedded (FFPE) tissues.
In the development of precision medicine, specimen preservation and transport are critical. One major advantage of our optimized FFPE workflow is its capacity for “International Specimen Analysis Service.” Unlike fresh frozen samples that require a stringent cold chain, FFPE specimens can overcome the logistical challenges of long-distance, cross-border transportation due to their inherent stability at room temperature. This breakthrough allows MarkerX to receive and analyze archival clinical samples from medical centers worldwide, providing high-quality data regardless of geographical barriers.
[Join the Conversation]
Are you interested in our optimized FFPE workflow for your research?We invite you to share your thoughts in the comments . Let’s explore the limitless possibilities of clinical mass spectrometry together!
▲A technical poster by MarkerX detailing the optimization of an FFPE tissue proteomic workflow from bulk tissue to microscopic foci. Utilizing laser-capture microdissection (LCM) and high-resolution mass spectrometry, this workflow achieves 100% concordance with pathological diagnosis for Amyloidosis, enabling high-quality protein identification even in minimal clinical specimens.
Media Contact
Debby Chen | Industry & Market Analyst, Office of the CEO
Marker X CO., LTD. (銳準生醫)